Last10K.com

Catalent, Inc. (CTLT) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

CTLT Quarterly Reports

Catalent, Inc.

CIK: 1596783 Ticker: CTLT

Exhibit 99.1
image11.jpg
Earnings Release


Investor Contact:
Catalent, Inc.
Paul Surdez
732-537-6325
investors@catalent.com

Catalent, Inc. Reports Third Quarter Fiscal 2020 Results
Q3'20 revenue of $760.6 million increased 23% as-reported, or 25% in constant currency, from Q3'19.
Solid organic revenue growth in all four segments.
Reporting net debt leverage of 3.8x as of March 31 vs 4.2x at December 31, 2019; more than $600 million in cash and cash equivalents on-hand; growth capital projects continue on schedule.
Completed the acquisition of MaSTherCell, a technology-focused cell and gene therapy development and manufacturing partner, on February 10, 2020.
Revising FY'20 financial guidance range modestly to reflect fluid COVID-19 situation; 
long-term fundamentals remain intact.
Revised guidance reflects revenue growth of 14-17%, unchanged from previous revenue growth guidance, and adjusted EBITDA growth of 17-21%, compared to adjusted EBITDA growth of 19-23% previously.

Somerset, N.J. - May 5, 2020 -- Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced financial results for the third quarter of fiscal year 2020, which ended March 31, 2020, and provided details on its response to the COVID-19 pandemic.

“In order to keep our 13,500 employees safe and continue to serve patients' needs, which include aiding the development of numerous potential treatments and vaccines for COVID-19, Catalent implemented responsive measures to the pandemic that allowed our more than 40 operating facilities around the world to continue production and the advancement of products and product candidates during this crisis,” said John Chiminski, Chair and Chief Executive Officer of Catalent, Inc. “Overall financial performance for the fiscal third quarter, which included solid organic growth in each of our four segments, was not meaningfully affected by the COVID-19 pandemic and its
1

The following information was filed by Catalent, Inc. (CTLT) on Tuesday, May 5, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Catalent, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Catalent, Inc..

Continue

Assess how Catalent, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Catalent, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
M & A
Other
Filter Subcategory:
All
Product
Earnings
Debt
Shares
Expense
Income
Cash Flow
Dividend
Geography
Other
Inside Catalent, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Changes In Shareholder's Equity
Consolidated Statement Of Changes In Shareholder's Equity Consolidated Statement Of Changes In Shareholders' Equity (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income / (Loss)
Consolidated Statements Of Operations
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies Recent Financial Accounting Standards (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies Research And Development Expense (Details)
Business Combinations
Business Combinations (Table)
Business Combinations Acquisition Purchase Agreement (Details)
Business Combinations Net Assets Acquired (Details)
Commitments And Contingencies
Definite Lived Long-Lived Assets
Definite Lived Long-Lived Assets (Tables)
Definite Lived Long-Lived Assets - Amortization Expense (Detail)
Definite Lived Long-Lived Assets - Other Intangible Assets Subject To Amortization (Detail)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities - Additional Information (Detail)
Derivative Instruments And Hedging Activities Net Investment Hedge Activity (Tables)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Earnings Per Share Earnings Per Share - Additional Details (Details)
Employee Retirement Benefit Plans
Employee Retirement Benefit Plans (Tables)
Employee Retirement Benefit Plans - Components Of Company's Net Periodic Benefit Costs (Detail)
Equity (Details)
Equity (Tables)
Equity And Accumulated Other Comprehensive Income (Loss)
Equity And Accumulated Other Comprehensive Income (Loss) (Tables)
Equity And Accumulated Other Comprehensive Income (Loss) - Accumulated Other Comprehensive Income (Loss) (Details)
Equity And Accumulated Other Comprehensive Income (Loss) - Equity (Details)
Equity And Accumulated Other Comprehensive Income (Loss) - Rollforward (Details)
Goodwill
Goodwill (Tables)
Goodwill - Rollforward (Detail)
Income Taxes
Income Taxes - Additional Information (Detail)
Leases
Leases (Tables)
Leases - Cost (Details)
Leases - Schedule Of Maturities Of Operating And Finance Lease Liabilities (Details)
Leases - Schedule Of Operating And Finance Leases Presented In The Balance Sheet (Details)
Leases - Schedule Of Supplemental Cash Flow Information (Details)
Long-Term Obligations And Other Short-Term Borrowings
Long-Term Obligations And Other Short-Term Borrowings (Tables)
Long-Term Obligations And Other Short-Term Borrowings - Long-Term Obligations, Presented Net Of Issue Discounts And Fees Paid To Lenders, And Other Short-Term Borrowings (Detail)
Long-Term Obligations And Other Short-Term Borrowings Fair Value Measurements Of Financial Instruments - Carrying Amounts And Estimated Fair Value Of Financial Instruments (Details)
Long-Term Obligations And Other Short-Term Borrowings Fair Value Of Financial Instruments (Tables)
Long-Term Obligations And Other Short-Term Borrowings Long-Term Obligations And Other Short-Term Borrowings (Details)
Other (Income)/ Expense, Net
Other Income And Expense (Details)
Other Income And Expense (Tables)
Redeemable Preferred Stock - Series A Preferred
Restructuring And Other Costs
Restructuring And Other Costs (Details)
Revenue Recognition
Revenue Recognition Contractual Liabilities (Details)
Revenue Recognition Contractual Liabilities (Tables)
Revenue Recognition Disaggregation Of Revenue By Geography (Details)
Revenue Recognition Disaggregation Of Revenue By Type Of Activity And Reporting Segment (Details)
Revenue Recognition Revenue Recognition (Tables)
Segment Information
Segment Information (Tables)
Segment Information - Net Revenue And Segment Ebitda (Detail)
Segment Information - Reconciliation Of Earnings / (Loss) From Continuing Operations To Ebitda (Detail)
Segment Information - Total Assets For Each Segment And Reconciling In Consolidated Financial Statements (Detail)
Segment Information, Ebitda, Reconciling Items (Detail)
Subsequent Events (Notes)
Subsequent Events,Loan Agreement (Details)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Inventory (Detail)
Supplemental Balance Sheet Information - Other Accrued Liabilities (Detail)
Supplemental Balance Sheet Information - Prepaid And Other Assets (Detail)
Supplemental Balance Sheet Information - Property And Equipment (Detail)

Material Contracts, Statements, Certifications & more

Catalent, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CTLT
CIK: 1596783
Form Type: 10-Q Quarterly Report
Accession Number: 0001596783-20-000056
Submitted to the SEC: Tue May 05 2020 8:31:34 AM EST
Accepted by the SEC: Tue May 05 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ctlt/0001596783-20-000056.htm